Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trainor

Showing results (1171-1180 of 1,242) with videos related to

Pageof 125
Sort By:
Nature Communications|March 10, 2026
Ribosomal modifications are associated with mesenchymal fate selection in the neural crest lineageIrina Poverennaya, Aliia Murtazina, Lei Li, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Journal of Medicinal Chemistry|March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamilyGretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Genetics in Medicine Open|June 16, 2025
Identification and characterization of short-chain dehydrogenase/reductase 3 (DHRS3) deficiency, a retinoic acid embryopathy of humansAkiko Soneda Hashimoto, Jianshi Yu, Christina Williams, et al.
Nature Chemical Biology|June 11, 2019
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Nature Chemical Biology|July 4, 2019
Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid TumorsAshvinikumar V Gavai, Claude Quesnelle, Derek Norris, et al.
Pageof 125

Showing results (1171-1180 of 1,242) with videos related to

Sort By:
Pageof 125
Nature Communications|March 10, 2026
Ribosomal modifications are associated with mesenchymal fate selection in the neural crest lineageIrina Poverennaya, Aliia Murtazina, Lei Li, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Journal of Medicinal Chemistry|March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamilyGretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Genetics in Medicine Open|June 16, 2025
Identification and characterization of short-chain dehydrogenase/reductase 3 (DHRS3) deficiency, a retinoic acid embryopathy of humansAkiko Soneda Hashimoto, Jianshi Yu, Christina Williams, et al.
Nature Chemical Biology|June 11, 2019
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Nature Chemical Biology|July 4, 2019
Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid TumorsAshvinikumar V Gavai, Claude Quesnelle, Derek Norris, et al.
Pageof 125